Literature DB >> 1318887

Urinary leukotriene E4 after exercise challenge in children with asthma.

Y Kikawa1, T Miyanomae, Y Inoue, M Saito, A Nakai, Y Shigematsu, S Hosoi, M Sudo.   

Abstract

To assess the role of sulfidopeptide leukotrienes in the pathogenesis of exercise-induced asthma (EIA), the urinary levels of leukotriene E4 (LTE4), a metabolite of LTC4 and LTD4, were measured by RIA before and after exercise in 13 children with EIA and 10 healthy children. Mass spectrometry was used to confirm the presence of LTE4 in urine and the specificity of the RIA. There was no significant difference in the urinary LTE4 levels before exercise between the children with asthma and healthy children (109 [21 to 265] versus 122 [45 to 156] pg/mg of creatinine; median and range). Urinary LTE4 levels increased significantly after exercise in the children with EIA (from 109 [21 to 265] to 196 [40 to 655] pg/mg of creatinine; median and range; p less than 0.05) but not in the healthy children. The children with asthma demonstrated no significant correlation between the LTE4 level after exercise and the degree of bronchoconstriction, as revealed by the maximal percent fall in the peak expiratory flow rate. Taken together with a recent study that pretreatment with a potent and selective LTD4 antagonist markedly attenuated EIA, our findings suggest that sulfidopeptide leukotrienes may play some role in the pathogenesis of this type of asthma with other factors also being involved in determining the overall airway response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1318887     DOI: 10.1016/0091-6749(92)90294-c

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  12 in total

Review 1.  The measurement of leukotrienes in human fluids.

Authors:  J Y Westcott
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  New treatments for asthma: the role of leukotriene modifier agents.

Authors:  D J Valacer
Journal:  J Natl Med Assoc       Date:  1999-08       Impact factor: 1.798

Review 3.  Clinical evidence with montelukast in the management of chronic childhood asthma.

Authors:  A Becker
Journal:  Drugs       Date:  2000       Impact factor: 9.546

Review 4.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

Review 5.  Cysteinyl leukotrienes in asthma: current state of therapeutic evaluation.

Authors:  I K Taylor
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

6.  Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist.

Authors:  T F Reiss; J B Hill; E Harman; J Zhang; W K Tanaka; E Bronsky; D Guerreiro; L Hendeles
Journal:  Thorax       Date:  1997-12       Impact factor: 9.139

7.  Peptidoleukotriene (PLT) release and absorption from the airways of the isolated perfused guinea pig lung following chemical and antigenic challenge.

Authors:  R A Kovelesky; P R Byron; J Venitz
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

Review 8.  G-protein-coupled receptors and asthma endophenotypes: the cysteinyl leukotriene system in perspective.

Authors:  Miles D Thompson; Jun Takasaki; Valérie Capra; G Enrico Rovati; Kathy A Siminovitch; W McIntyre Burnham; Thomas J Hudson; Yohan Bossé; David E C Cole
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

9.  Urinary excretion of 9α,11β-prostaglandin F2 and leukotriene E4 in patients with exercise-induced bronchoconstriction.

Authors:  Tae-Rim Shin; Joo-Hee Kim; Cheol-Hong Kim; In-Gyu Hyun; Jeong-Hee Choi
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

10.  Phase 2 trial of montelukast for prevention of pain in sickle cell disease.

Authors:  Joshua J Field; Adetola Kassim; Amanda Brandow; Stephen H Embury; Neil Matsui; Karina Wilkerson; Valencia Bryant; Liyun Zhang; Pippa Simpson; Michael R DeBaun
Journal:  Blood Adv       Date:  2020-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.